权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project 1: Understanding normal tissue toxicity to identify patients most likely to benefit from proton therapy.

项目 1：了解正常组织毒性，以确定最有可能从质子治疗中受益的患者。

基本信息

批准号：
10491847
负责人：
HARALD PAGANETTI
金额：
$ 56.33万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-21 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10491847
关键词：
3-Dimensional Address Biological Biological Factors Biological Markers Blood Brain Brain Stem Cardiotoxicity Cardiovascular system Charge Clinical Clinical Data Clinical Trials Common Terminology Criteria for Adverse Events Complication Consensus Dimensions Disease Dose Educational workshop Frequencies Functional disorder Grant Heart failure Hepatotoxicity Image Immune response Institution Joints Knowledge Machine Learning Modality Modeling Myocardial Infarction Myocardial dysfunction Necrosis Noise Normal tissue morphology Organ Outcome Patients Photons Positron-Emission Tomography Probability Proton Radiation Protons Radiation Radiation Tolerance Radiation therapy Radiobiology Relative Biological Effectiveness Research Risk Site Statistical Models System Toxic effect Treatment outcome Treatment-related toxicity University of Texas M D Anderson Cancer Center Variant Weight base conventional therapy falls imaging biomarker irradiation novel novel strategies particle patient stratification precision medicine proton beam proton therapy radiation risk response treatment site tumor two-dimensional

项目摘要

PROJECT 1 - PROJECT SUMMARY A potential benefit of proton beam therapy compared to conventional therapy is expected for many treatment sites if solely judged by the dose distribution, i.e. physical parameters. Biological differences between protons and photons are currently only considered by applying a constant weighting factor to proton doses, i.e. a proton relative biological effectiveness (RBE) of 1.1. There is an urgent need for additional research to examine whether spatial variations in dose and RBE within organs at risk can explain adverse treatment outcomes. The potential difference in normal tissue toxicity between proton and photon irradiation can only be assessed with studies with a substantial amount of clinical data because the frequencies of most overt toxicities in radiation therapy is low, thus causing variations to be typically within the noise of patient specific radiosensitivity. There is a significant amount of clinical data available at our two institutions and equally as important, expertise in assessment of toxicities based on blood, imaging and dosimetric biomarkers. We hypothesize that there are fundamental differences in normal tissue toxicities between proton and photon radiation due not only to differences in the distribution of dose but also variations in RBE for normal tissue toxicities, which are currently poorly understood. We aim to 1) understand the differences in normal tissue toxicities between protons and photons by assessing dose response relationships, 2) identify biomarkers to inform relative normal tissue complication probabilities to replace simple RBE concepts, and 3) advance precision medicine concepts to proton radiotherapy by identifying patients that will benefit. Ultimately our approach will lead to novel outcome modeling concepts applicable to both proton and photon therapy.

项目1 -项目总结